Apricot Therapeutics AG
Data-driven drug discovery for targeted medicine
Apricot BIO, a spin-off from the University of Zürich, is positioning itself to become the “Google maps” of the tumor cell by combining drug perturbations, image-based phenotypic profiling, systems biology approaches, and robust predictive modelling. One of the biggest challenges in personalized cancer treatment is that currently only a small proportion of patients are eligible for a targeting-therapy drug. Further, among those treated, most cancer patients are either inherently resistant or eventually acquire resistant to such therapies. By using a novel technological platform that directly measures drug activity in patient`s tumor cells, APx`s goal is to provide evidence-based drug recommendations to clinicians. Thus, providing wider access to personalized therapy.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
30.06.2025
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
02.06.2025
Apricot Therapeutics: The Venture Leader Biotech advancing data-driven drug discovery for targeted medicine (venturelab.swiss)
06.05.2025
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
25.03.2025
Venture Leaders Biotech 2025: 10 innovative startups selected for Boston roadshow (venturelab.swiss)
06.02.2025
APx agrees to showcase the 4i DRP platform for 3 cancer indications with German based consortium
18.11.2024
APx signs OVPrecision 2-year ovarian cancer trial with UniBas, ETH and UZH
15.05.2024
In collaboration with Children's Hospital Zurich / Kinderspital Zürich - 2 projects concluded over 6 months.
18.01.2024
APx signs license agreement with University of Zurich for exclusivity on 2 patent families underpinning our 4i Platform technology
01.01.2023
APx signs first deal with Basel based Monte Rosa Therapeutics AG
No Jobs
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Biotech
Apricot Therapeutics AG
Data-driven drug discovery for targeted medicine
Website:
www.Apricot-BIO.com
Headquarter:
Zürich
Foundation Date:
September 2022
Technology:
- Biotech
Sectors:
- Big Data
- Biotech
- Cancer
- Digital Health
- Drug development platforms
- Drug discovery
- Medtech
- Services for companies
- Small molecule drugs
Support received
